1. Indonesia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
PT Pyridam Farma Tbk

PT Pyridam Farma Tbk

IIDX:PYFA
179.00
IDR
+2.00
(+1.13%)
-30.68EPS
1.96TMarket Cap
PT Pyridam Farma Tbk
IDX:PYFA
(Indonesia Stock Exchange)

Recent

price

179.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
IDR
56.52
60.63
70.91
77.26
89.2
87.41
87.05
89.48
100.49
99.16
111.31
253
287.07
281.71
226.29
245.66
266.32
Revenue per Share
1.68
2.08
2.13
2.49
1.07
1.24
2.06
2.86
3.39
3.75
8.87
2.2
110.44
-34.2
-38.91
-33.79
-30.68
Basic EPS, GAAP
2.63
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
0.62
- -
0.86
- -
- -
- -
- -
3.73
- -
- -
Dividend per Share
30.99
33.06
35.19
37.76
38.96
40.62
42.34
43.68
47.72
50.05
63.25
67.05
177.41
143.18
92.51
68.26
60.89
Book Value per Share
30.97
33.05
35.17
37.73
38.92
40.58
42.3
43.64
47.67
49.99
63.14
49.06
155.89
118.48
-137.84
-181.75
-208.51
Tangible Book Value per Share
2,492
2,492
2,492
2,492
2,492
2,492
2,492
2,492
2,492
2,492
2,492
2,492
2,492
2,492
8,488
11,237
11,237
Basic Weighted Avg Shares
140,858
151,094
176,731
192,556
222,302
217,844
216,952
223,002
250,446
247,115
277,398
630,530
715,425
702,068
1,920,812
2,760,422
2,992,542
Sales/Revenue/Turnover
4.02
4.64
5.51
6.21
4.37
4.36
4.4
5.09
5.07
5.59
11.17
3.67
-4.19
-1.2
-1.52
-6.11
-4.07
Operating Margin (%)
- -
- -
2,626
3,220
3,759
2,900
2,827
2,844
1,758
1,284
2,438
8,584
15,661
13,252
70,229
96,763
101,934
Depreciation Expense
4,199
5,172
5,308
6,196
2,661
3,087
5,146
7,127
8,447
9,343
22,104
5,479
275,241
-85,221
-330,247
-379,670
-344,748
Net Income, GAAP
25.52
27
33.41
27.11
36.81
32.23
27.04
25.75
25.36
25.37
25.43
37.82
- -
- -
- -
- -
- -
Effective Tax Rate (%)
2.98
3.42
3
3.22
1.2
1.42
2.37
3.2
3.37
3.78
7.97
0.87
38.47
-12.14
-17.19
-13.75
-11.52
Profit Margin (%)
31,428
37,522
40,168
26,188
30,083
36,212
45,173
56,119
58,245
68,748
84,594
74,593
243,604
274,773
334,778
275,743
-278,884
Working Capital
455
1,377
7,460
18,222
11,054
4,112
856
512
6,676
6,074
8,008
362,803
750,231
835,557
3,194,107
4,392,726
4,329,925
LT Debt
77,225
82,397
87,705
94,112
97,097
101,222
105,509
108,856
118,928
124,726
157,632
167,101
442,357
357,060
1,039,546
985,181
899,278
Total Equity
4.69
5.36
5.33
4.61
4.35
4.81
5.59
6.89
8.04
7.83
14.17
8.03
- -
- -
- -
- -
- -
Return on Invested Capital (%)
5.94
6.36
6.08
6.39
4.34
4.76
5.57
7.04
8.01
7.81
14.06
7.8
- -
- -
- -
- -
- -
Return on Capital (%)
5.59
6.48
6.24
6.82
2.78
3.11
4.98
6.65
7.42
7.67
15.66
3.37
90.36
-21.33
-47.3
-42.03
-44.76
Return on Common Equity (%)

Capital Structure

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
448,680
948,170
1,056,205
LT Borrowings
3,259,004
2,937,121
3,099,519
LT Finance Leases
1,133,722
1,175,302
1,230,405
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11,237
11,237
11,237
Market Capitalization
5,348,666
3,483,375
1,955,194

Working Capital

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,421,704
1,511,757
1,632,861
Cash, Cash Equivalents & STI
102,888
51,071
130,306
Accounts Receivable, Net
755,689
828,626
870,286
Inventories
483,971
540,998
546,957
Total Current Liabilities
1,145,961
1,765,948
1,911,745
Payables & Accruals
- -
- -
- -
ST Debt
448,680
948,170
1,056,205
Deferred Revenue
- -
- -
- -

Growth Rates

IDR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
38.53%
67.47%
-5.23%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
529.08%
1,003.99%
14.97%
Sales/Revenue/Turnover
38.18%
71.24%
43.71%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
151,636
255,685
754,509
758,982
1,920,812
2025
685,456
699,947
674,838
700,181
2,760,422
2026
766,534
850,990
- -
- -
- -

Quarterly Earnings Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-17.3
-6.22
-8.81
-10.32
-38.91
2025
-8.15
-10.91
-13.58
-1.23
-33.79
2026
-7.2
-8.67
- -
- -
- -

Quarterly Dividends Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
-2.68
3.73
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
PT Pyridam Farma Tbk (PYFA.JK) manufactures and distributes pharmaceutical products, including generic drugs, branded generics, and over-the-counter (OTC) medicines; it also produces active pharmaceutical ingredients (APIs), herbal supplements, and health supplements under its own brands such as Pyridam and various licensed portfolios. The company operates primarily in the healthcare and pharmaceutical industry, serving hospitals, clinics, pharmacies, and retailers with a focus on therapeutic areas like anti-infectives, analgesics, vitamins, and chronic disease treatments. Founded in 1974 and headquartered in Jakarta, Indonesia, PT Pyridam Farma Tbk maintains production facilities in Indonesia and distributes products domestically across major islands including Java, Sumatra, and Sulawesi, with exports to select Southeast Asian markets. In recent developments, the company completed a significant rights issue in 2024 raising approximately IDR 100 billion to expand manufacturing capacity and entered a strategic distribution partnership with a leading regional healthcare distributor in early 2025; it also launched a new line of probiotic supplements targeting post-pandemic gut health needs and acquired a small herbal medicine producer to bolster its natural products segment. These initiatives support ongoing business expansion amid Indonesia's growing pharmaceutical demand, with no major name changes or reorganizations reported in the last two years.